Feasibility of conducting clinical trials on “Ayurveda combination” as a medicine for
treatment of COVID-19 patients in the NHS: First professional assessment was submitted by Aarogyam (UK) and University of Warwick to High Commissioner, India as formal report to Government of India.
June 1, 2020 Aarogyam (UK) joined the UK India joint collaboration on herbal research where potential of formal partnership was discussed with leading University and pioneers of Ayurveda in the UK. As follow up, Aarogyam and University of Warwick in association with NHS.
as proposed, A therapeutic intervention of Ayurveda, as per the protocol designed by Ministry of AYUSH (AYUSH) will be administered to 50% of the recruited individuals for the number of days prescribed by the Govt of India. The “AiM COVID-19 app “developed by PI –
Analytics will be used to predict, monitor, and analyse the efficacy of the Ayurvedic intervention. The trial duration is estimated to be 3-to-6 months; this will be set by AYUSH.
Report also discuss the potential of Ayurveda trial with in NHS. Previously, an ayurvedic intervention trial has been conducted in the NHS clinics in the UK – in fact, in 2019 itself: As the article https://www.telegraph.co.uk/science/2019/03/19/nhs-trial-ayurvedic-herbal-remedy-cut-antibiotics-coughs-colds/ shows, the NHS started a clinical trial last year on an Ayurvedic remedy (Andrographis) in 20 NHS clinics in South East England; the points of contact for this trial are (i) Dr Michael Dixon (https://en.wikipedia.org/wiki/Michael_Dixon_(doctor)) who was a former Chair of
the NHS Alliance and a former President of the NHS Clinical Commissioners and (ii) Dr Euan
MacLennon (https://www.herbalreality.com/expert-opinion/euan-maclennan/) who is a Herbal & Sustainability Director at Pukka Herbs and a Medical Herbalist at an NHS clinic in London.